Enhanced Genomics

Enhanced Genomics is a private, pre-revenue biotechnology company leveraging a proprietary 3D multi-omics platform, GenLink™, to decode the genetic drivers of disease and identify novel therapeutic targets. Spun out from pioneering research at the Babraham Institute, the company operates both an in-house discovery program focused on autoimmune diseases and selectively partners with other biopharma entities. Its core value proposition is a 10x faster target identification process and a claimed 2x increase in drug development success through genetic validation.

GenLink™, a 3D multi-omics platform that integrates genomic, transcriptomic, and epigenomic data from primary human cells to map the spatial folding of the genome and reveal causal biological networks for target identification.

Enhanced Genomics competes in the crowded genomics-driven drug discovery space against companies like Recursion Pharmaceuticals, Insitro, and Genomics plc, as well as internal efforts at large pharma. Its differentiation lies in the specific focus on 3D genomic spatial organization to establish causality, a niche with high technical barriers but unproven clinical translation.